OncorMed offers genetic testing for inherited cancers:
This article was originally published in Clinica
OncorMed has launched a test for mutations in the recently discovered BRCA2 breast and ovarian cancer gene. The company which is based in Gaithersburg, Maryland, is providing the new service in combination with its existing BRCA1 test. Approximately 185,000 patients will be diagnosed with breast cancer this year in the US. Between 5 and 10% of breast cancer is hereditary, with BRCA1 mutations accounting for about 45% and BRCA2 mutations accounting for about 35% of these cases.
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.